Cosmos Health (COSM) announced the appointment of Professor Dimitrios Trafalis as Head of Oncology at the company’s Research and Development division. Trafalis currently serves as a Professor of Pharmacology and Clinical Pharmacology at the Faculty of Medicine, National and Kapodistrian University of Athens. Trafalis will lead research initiatives focusing on the design and execution of preclinical and clinical development strategies, regulatory support, and studies aimed at addressing critical oncology challenges. Specifically, his role includes overseeing preclinical and clinical protocols, making strategic decisions in research, and presenting key developments at global medical conferences and in international scientific journals.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COSM:
- Cosmos Health CEO, CFO collectively increase stake by 343,000 shares
- Cosmos Health files to sell common stock, warrants, no amount given
- Cosmos Health integrates bitcoin, ethereum as treasury reserve assets
- Cosmos Health says reorganization is underway to streamline costs
- Cosmos Health anticipates ‘substantial value creation’ by 2027
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue